Home|Journals|Articles by Year|Audio Abstracts

Original Article

Interest of propanolol in the treatment of infantil hemangiomes about a retrospective study of 94 cases

Salima Baya, Ognyan Zlatev, Ivan Inkov, Badr Tarif, Nawfal Fejjal.

Cited by 0 Articles

Infantile hemangioma ( HI ) is the most common children ‘s vascular tumor . It is a benign tumor with essentially clinical diagnosis. Despite its benign character, treatment is required in many situations.
This is a retrospective study of 94 outpatients treated with propranolol and followed in the pediatric plastic surgery department (surgery C) at the Rabat Children's Hospital for a period of 4 years from, 2012 to 2017.
The average age of children treated was 3 months, with a female predominance (n = 60, 74%).
Tuberous HI was the most common clinical type (n = 68, 70.1%), the single form was predominant (n = 85, 90%), cervico-cephalic localization was the most common (n = 75, 72.1%), labial localization accounted for 40% (n = 30), 6 segmental HIs were reported (6.4%) including 3 PHACES syndromes including Dandy Walker syndrome. The average diameter of HI was 4cm.
Therapeutic indications were for : functional risk (n = 44, 43.5%), ulceration (n = 35, 43.5%), aesthetic risk (n = 20, 20%), and life risk (n = 35, 43.5%), the dosage was 3 mg / kg / day of propanolol . The average duration of treatment was 9 months, the tolerance was good. Only one case of malaise has been reported. Efficacy was very high with 79% success (excellent response (n = 22, 24%), good response (n = 52, 55%)
The follow-up after the end of the treatment did not objectify any recurrence.

Key words: hemangioma, benign tumor, child, evolution, abstention propranolol, benefit - risk, functional and vital prognosis

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.